Konveril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Konveril

What is Konveril and What Type of Medicine is It?

Konveril is a prescription-only, synthetic cardiovascular agent used to manage high blood pressure and support heart function, representing a standard therapeutic action in cardiovascular care. The active substance in the medicine is Enalapril maleate, which is classified within the pharmacological class of Angiotensin-Converting Enzyme (ACE) inhibitors. This classification defines the drug's role as a specialized antihypertensive agent used to modulate the circulatory system. Konveril is a single active ingredient product that functions as a pro-drug. This means the compound Enalapril undergoes metabolic conversion in the body to its active therapeutic form, Enalaprilat, before its effects are fully realized.

Composition and Physical Form of Konveril

The medication is formulated for ingestion as an oral tablet for systemic action throughout the body. Konveril is presented as film-coated tablets, containing the active ingredient Enalapril maleate along with solid pharmaceutical excipients necessary for the tablet structure. This oral form is the standard method for administering Enalapril, allowing for the absorption of the pro-drug through the digestive system. This delivery method is a common clinical application for long-term management of cardiovascular conditions.

General Purpose and Cardiovascular Benefit

The general purpose of Konveril is to ease the workload on the heart by relaxing and widening the blood vessels throughout the circulatory system. As an ACE inhibitor that acts as a Renin-Angiotensin-Aldosterone System (RAAS) modulator, the medicine decreases the body’s formation of vasoconstricting agents. This results in vasodilation and lower peripheral vascular resistance. This action helps to stabilize circulation, providing cardioprotective and renoprotective support for the vascular system in patients with conditions such as chronic hypertension.

Regulatory References

  1. A review published by the National Library of Medicine

What side effects are possible with Konveril?

Konveril’s safety profile, typical of its class (ACE inhibitors), is defined by a range of adverse reactions, which are categorized by frequency and the body's organ systems involved, according to regulatory standards.

Reported Adverse Reactions

Classification Examples of Reactions
Very Common (ge 1/10) Headache, dry cough
Common (ge 1/100 to < 1/10) Dizziness, fatigue, nausea, low blood pressure (hypotension)
Uncommon (ge 1/1000 to < 1/100) Palpitations, skin rash, vertigo, orthostatic hypotension
Rare (ge 1/10000 to < 1/1000) Angioedema, renal dysfunction, hepatitis

Serious and Clinically Significant Safety Information

The most serious safety concerns documented in regulatory sources are Angioedema (swelling of the face, tongue, and throat, which can be life-threatening), severe Hypotension (excessively low blood pressure, particularly upon initiation or dose increase), and rare instances of Hepatic Failure or Renal Failure.

Safety Restrictions and Special Populations

  • Pregnancy: Konveril is strictly contraindicated during the second and third trimesters of pregnancy due to the documented risk of fetal injury or death, including fetal kidney failure and skull defects.
  • Hypersensitivity: The medicine is contraindicated in any patient with a prior history of angioedema related to an ACE inhibitor or with hereditary/idiopathic angioedema.
  • Renal Risk: Caution is advised, and monitoring is required for patients with pre-existing renal conditions or bilateral renal artery stenosis, as there is a risk of severe renal impairment or failure.
  • Drug Interactions: Use is contraindicated in combination with aliskiren-containing products in patients with diabetes or moderate-to-severe kidney impairment.

The official safety information highlights the need for careful patient selection and systematic monitoring of blood pressure, kidney function, and signs of angioedema. The risks are clearly structured to inform the understanding of potential harms relative to the expected frequency and severity.

Overdose and Emergency Response

Konveril Overdose and When to Seek Help

This information is based on official government-authorized prescribing information for the active ingredient in Konveril (Enalapril).

Documented Overdose Manifestations

Overdose of Konveril primarily affects the cardiovascular system. Documented signs and symptoms include profound hypotension (severely low blood pressure), syncope (fainting), dizziness, stupor, and alterations in heart rate, such as tachycardia (rapid heart rate) or bradycardia (slow heart rate).

Life-Threatening Risks and Emergency Action

Severe overdose can progress beyond simple hypotension to cause life-threatening complications, including cardiovascular collapse (shock) and acute renal (kidney) failure. The official labeling specifies that immediate medical attention is required for the treatment of severe hypotension and associated life-threatening events. Users must seek urgent medical help or contact a poison control center immediately if an overdose is suspected or confirmed.

Management and Monitoring

No specific pharmacological antidote for Konveril is listed in regulatory information. Management is supportive, focusing on volume expansion (e.g., intravenous fluid administration) to correct low blood pressure. Monitoring of vital signs, serum electrolytes, and kidney function is critical. In cases of severe toxicity, the active metabolite is known to be removable by hemodialysis.

Therapeutic Uses of Konveril

What Konveril Treats: Main Uses and Benefits

Konveril is primarily used to offer short-term, supportive relief for various forms of symptomatic discomfort, relevant in contexts marked by increased discomfort or tension. It is commonly used when short-term symptomatic assistance is needed, applied across domains where additional symptomatic support is required. This therapeutic approach is applied across different clinical scenarios where temporary assistance may be used to manage noticeable physiological strain.


What Konveril Helps Manage

Konveril is considered relevant across several categories, including the management of symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. It is applied in clinical settings that involve acute or unstable symptom patterns and in situations involving recurrent or episodic manifestations. It generally supports the patient during difficult episodes by easing distress.


Relief for Sudden or Intensifying Symptom Clusters

This domain addresses symptom clusters that appear abruptly or worsen quickly, relevant for managing symptoms that interfere with daily comfort. Konveril helps address symptom clusters that may become intense or disruptive, and generally supports the patient during difficult episodes.

Quick Fact: It assists with managing symptoms associated with acute or episodic changes.


Assistance in Situations of Heightened Discomfort

Relevant in contexts involving heightened systemic burden, this section covers clinical contexts where short-term assistance in symptom stabilization is important. Konveril provides support that contributes to easing the overall symptom load, and may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Who can and cannot use Konveril?

Eligibility for Konveril (Enalapril maleate) use is defined by government regulatory documents based on contraindications, patient history, and certain physiological states.

Eligibility scope
Populations for whom use is allowed (as stated in label): Adults for hypertension or heart failure.
Populations for whom use is not recommended (if applicable): Neonates, infants under one month, and women in the first trimester of pregnancy.
Populations for whom use is contraindicated: Patients with a history of angioedema related to any ACE inhibitor, or those with hereditary or idiopathic angioedema. Contraindicated during the second and third trimesters of pregnancy.
Age-related eligibility rules
Minimum Age: Restricted use for children with hypertension, generally from six years and older with adequate renal function.
Older Adults: Use requires caution due to a higher likelihood of age-related changes in renal function.
Condition-specific eligibility rules
Renal Impairment: Not recommended for pediatric patients with severe renal impairment (GFR <30 mL/min/1.73 m^2). Use requires caution in all patients with pre-existing renal or hepatic impairment.

Official eligibility statements: Contraindications strictly prohibit use in patients with angioedema history or during late pregnancy. Use is also contraindicated with aliskiren in patients with diabetes or moderate renal impairment, or within 36 hours of taking sacubitril/valsartan.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Konveril through non-negotiable prohibitions based on hypersensitivity, a history of angioedema, and the risk associated with use during late pregnancy. Furthermore, eligibility is limited by requirements for caution in those with compromised renal or hepatic function, which dictates monitored use.

What should I know about interactions with other medicines?

Konveril Interactions with other medicines and products

This section summarizes the officially documented interactions for Konveril (enalapril maleate), an Angiotensin-Converting Enzyme (ACE) inhibitor, based on authoritative government regulatory sources.

Formally Documented Contraindicated Combinations

The regulatory label strictly prohibits co-administration with a neprilysin inhibitor, such as sacubitril (found in products like sacubitril/valsartan), due to a significantly increased risk of angioedema. A mandatory timing restriction applies: Konveril must not be administered within 36 hours before or after the sacubitril-containing medicine. Additionally, use with aliskiren is contraindicated in patients with diabetes mellitus or in those with renal impairment (specifically, GFR <60 mL/min).

Pharmacodynamic and Exposure-Altering Interactions

  • Potassium-Affecting Agents: The combination with Potassium-Sparing Diuretics (e.g., spironolactone) and Potassium Supplements is associated with an elevated risk of hyperkalemia, a documented alteration of serum potassium levels.
  • Other Antihypertensives and NSAIDs: Combining Konveril with other blood pressure-lowering agents may result in additive hypotension. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may lead to a deterioration of renal function.
  • Lithium: Konveril may cause a reversible increase in serum lithium concentrations and toxicity, requiring careful monitoring.
  • Food/Alcohol: Regulatory data confirm that the absorption of enalapril is not influenced by food. However, co-use with alcohol may increase the risk of dizziness.

Mechanism of Action

Konveril is the prodrug enalapril maleate, which is metabolically converted by hepatic carboxylesterase 1 (CES1) to its active metabolite, enalaprilat. Enalaprilat functions as a competitive inhibitor of the somatic angiotensin-converting enzyme (ACE), a zinc-containing peptidyl dipeptidase.

The biological target, ACE, is responsible for the catalytic conversion of angiotensin I (a decapeptide) to the potent vasoconstrictor, angiotensin II (an octapeptide). Inhibition of ACE by enalaprilat disrupts this key step in the Renin-Angiotensin-Aldosterone System (RAAS) cascade, resulting in a reduction of circulating and tissue-level angiotensin II concentrations.

The intracellular consequence of reduced angiotensin II is decreased stimulation of the angiotensin II type 1 (AT1) receptor. This ultimately leads to two primary downstream effects: a decrease in aldosterone secretion from the adrenal cortex and an attenuation of direct vasoconstriction signals on vascular smooth muscle.

System-level physiological modulation involves a resulting reduction in overall systemic peripheral vascular resistance and decreased aldosterone-mediated renal retention of sodium and water. Furthermore, ACE inhibition impedes the enzymatic degradation of bradykinin, leading to its accumulation and contribution to vasodilation.

Dosage and Administration Information

How to Use Konveril

Konveril (Enalapril maleate) is administered according to standard clinical protocols for its long-term use in cardiovascular management. The primary route of administration is oral, available as tablets in strengths from 2.5 mg to 20 mg. An intravenous (IV) route is also used for the active metabolite, Enalaprilat, in specific acute settings.


Dosing and Frequency

Dosage is initiated at a low level and often requires upward titration over several weeks to reach a suitable maintenance level. For adult hypertension, the usual initial oral dose is 5 mg once daily, which may be lower (2.5 mg) if the patient is already taking diuretic medication. The medicine is generally taken once or twice daily, and tablets can be consumed with or without food. The maximum daily dose for oral use is 40 mg.


Special Administration Conditions

Administration procedures are conditional on patient health status and age. The initial dose is typically reduced to 2.5 mg daily for patients with severe renal impairment. Pediatric dosing is determined by body weight. Furthermore, the start of Konveril therapy for conditions like heart failure occurs under close medical supervision. If a dose is missed, the standard procedure involves skipping the forgotten dose and maintaining the regular schedule, without taking a double dose. The IV form is administered as a slow infusion over 5 minutes.

Recent Clinical Evidence

Clinical research on Konveril (Enalapril maleate) has primarily utilized large, randomized controlled trials (RCTs) and long-term observational studies across its main areas of use.

Evidence for the Management of Chronic Physiological Strain

For the management of chronic physiological strain (associated with elevated blood pressure), research explored its use in adults with uncomplicated hypertension, older adults, and pediatric patients over one month of age. Studies monitored changes in systolic and diastolic blood pressure, tracked major cardiovascular events like stroke, and examined kidney-related outcomes in patients with co-occurring conditions such as diabetes. Findings related to blood pressure changes were tracked differently across various racial cohorts included in the study summaries.

Evidence for Supportive Relief in Heightened Systemic Imbalance

Evidence for supportive relief in heightened systemic imbalance (related to heart failure) comes from landmark, multi-center, placebo-controlled trials. These studies primarily focused on adults with chronic heart failure or asymptomatic left ventricular dysfunction. The main outcomes tracked included all-cause mortality rates, the frequency of events requiring hospitalization, and patient functional status assessed using tools like the NYHA classification. Research observed these patient cohorts over periods ranging from six months to five years.

Research Limitations and Uncertainty

Research in special populations examined Konveril in children with hypertension, although available data remain insufficient for those with severe kidney problems. A key limitation across the research is that results apply only to the populations studied; individuals with very complex diseases were often excluded from the large trials. Subgroup findings regarding specific dose levels studied in heart failure trials are uncertain, and overall long-term effects on functional status for all patient groups are not fully established.

Key Studies & References Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)

Frequently Asked Questions (FAQ)

Common questions about Konveril (FAQ)


Q: Can Konveril be used by people who have diabetes?

The official product information specifies that Konveril is strictly prohibited (contraindicated) for patients with diabetes who are also taking a medicine containing aliskiren. Official documentation mentions that patients with diabetes may require close monitoring of blood pressure and kidney function during treatment.

Q: Does Konveril interact with common pain relievers like ibuprofen or acetaminophen?

Official documents indicate that Konveril may interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, which can lead to a deterioration of kidney function. The product label does not specifically mention an interaction warning for acetaminophen, though NSAID interactions are documented.

Q: Is Konveril safe to use during pregnancy or while breastfeeding?

Konveril is strictly contraindicated during the second and third trimesters of pregnancy due to documented risks of fetal harm or death. While small amounts of the medicine may pass into breast milk, official documentation suggests that the decision regarding continuing the medicine or breastfeeding should be made in consultation with a healthcare professional.

Q: How does Konveril get processed by the liver or kidneys?

Konveril is a pro-drug that is primarily converted into its active therapeutic form (enalaprilat) in the liver. Both the active and inactive forms are then primarily eliminated from the body by the kidneys.

Q: Is Konveril considered a medication that needs regular blood monitoring?

Yes. The product label advises that close monitoring of certain body metrics is necessary before and during treatment. This monitoring includes checking blood pressure, kidney function (creatinine), and the levels of electrolytes, such as potassium, in the blood.

Q: How quickly does Konveril typically start working after I begin taking it?

According to official regulatory information, the blood pressure-lowering effect typically starts within one hour of taking a dose, reaching its maximum effect approximately four to six hours later. However, achieving the full therapeutic effect (optimal blood pressure reduction) may require several weeks of continued treatment.

Q: Can Konveril cause weight gain or weight loss?

Significant weight changes are not commonly listed as a direct side effect in product documentation. However, sudden or unexplained weight gain may be a sign of more serious conditions, such as fluid retention or kidney problems, and is a symptom that should be promptly reported to a healthcare provider.

Q: Is Konveril known to affect sleep patterns or cause insomnia?

Reports of insomnia (difficulty sleeping) have been included as a less common adverse event in some product information summaries. Changes in mood, including reports of depression or confusion, have also been documented.

Q: How long do most people need to stay on Konveril?

Konveril is typically prescribed for the long-term management of chronic cardiovascular conditions, such as high blood pressure and heart failure. It is generally prescribed for daily intake and should only be discontinued or changed under the direction of a healthcare professional.

Q: Can Konveril affect my ability to drive or operate machinery?

Because Konveril can occasionally cause dizziness, lightheadedness, or fatigue, caution is recommended when driving or operating machinery until the patient understands how the medicine affects them.

Q: Is Konveril a controlled substance?

No, Konveril (enalapril maleate) is classified as a prescription-only medicine and is not listed as a federally controlled substance.

Q: Does Konveril have any known interactions with herbal supplements?

Regulatory documentation often notes that there is insufficient data to confirm the safety of herbal remedies with Konveril, as they are typically not subjected to rigorous drug interaction testing. For this reason, official patient information stresses the importance of disclosing all supplements to a healthcare professional.

Q: Can Konveril cause changes in mood or anxiety levels?

Changes in mood, including reports of depression, confusion, or nervousness, have been reported as adverse events in product documentation.

Q: Is there a generic version of Konveril available?

Yes, the active ingredient in Konveril, enalapril maleate, is widely available as a generic medication. The generic version must meet regulatory standards that ensure it is bioequivalent to the brand-name product, meaning it is expected to work in the body in the same way.

Q: Why is Konveril sometimes prescribed with other medications?

Konveril may be used in combination with other anti-hypertensive agents to achieve adequate blood pressure management. For conditions like heart failure, it is commonly used in addition to other key therapies, such as diuretics or beta-blockers, as part of a comprehensive treatment plan.

Q: Can Konveril affect the results of certain medical tests?

Yes, Konveril may cause changes in laboratory test results. The need for regular monitoring indicates that it can influence results related to blood cell counts, electrolytes, and kidney function tests.

Q: Does Konveril come with a patient medication guide?

Yes, regulatory standards require that the medicine is supplied to the patient with a patient information leaflet or medication guide. This document details necessary instructions for use, possible side effects, and storage information.

Q: Does Konveril cause dry mouth or dry eyes?

Dry mouth has been reported as a less common adverse event in some product information summaries. Dry eyes is not explicitly listed among the adverse reactions for the single-ingredient product.

Q: What does official documentation say about Konveril and fertility?

Official documentation indicates that there is currently no clear evidence suggesting that Konveril reduces fertility in men or women.

Q: Are there any specific lifestyle changes recommended when using Konveril?

Patient information may include general recommendations for supporting the treatment of conditions like high blood pressure. These often suggest lifestyle adjustments, such as limiting alcohol and salt intake, engaging in regular exercise, and maintaining a healthy weight. These adjustments should be made in consultation with a healthcare professional.

Q: How long does Konveril stay in your system after the last dose?

The active form of the medicine (enalaprilat) has an effective half-life for accumulation of approximately 11 hours following multiple doses.

Q: Does the time of day I take Konveril matter?

Official patient information recommends taking the medicine at about the same time each day to help maintain consistent levels in the body and support adherence.

Q: What is the difference between the brand name and generic version of Konveril?

The generic version of the active ingredient (enalapril maleate) must meet regulatory standards that ensure it is bioequivalent to the brand-name product, meaning it is expected to perform the same way in the body as the brand name.

Q: What is Konveril's classification in terms of safety during use?

Konveril's safety is defined by specific contraindications (prohibitions) and warnings listed in the product label. These include strict prohibitions during late pregnancy and in patients with a history of angioedema (severe swelling), and the requirement for extreme caution and monitoring in patients with impaired kidney function.

Q: Can Konveril cause changes in vision?

Blurred vision has been reported as a documented adverse event in some product information summaries.

How should Konveril be stored and disposed of?

The official documentation for Konveril (enalapril maleate) mandates specific requirements to preserve the tablets' integrity and ensure safe handling.

️ Storage and Protection Constraints

The tablets must be stored at controlled room temperature, generally defined as 15 C to 30 C. It is mandatory to keep the container tightly closed and protect the medicine from moisture to maintain stability. Konveril must be stored away from excessive heat and must not be frozen.

️ Child Safety and Disposal

As required by regulatory authorities, the medication must be kept out of the sight and reach of children in a secure location. For disposal, unused or expired Konveril must not be thrown away via wastewater or household waste. Patients should follow local and national regulations for pharmaceutical waste and consult a pharmacist for guidance on approved disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Konveril found in:

A-Z Index: